Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | ARF6 | P62330 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100204 | 1.00 | LTA4H (0.38) | LTA4HFFAR1PPARDPPARAPDE10A | |
| SCHEMBL21531518 | 0.95 | LTA4H (0.35) | LTA4HFFAR1PPARDPPARAPDE10A | |
| SCHEMBL21531513 | 0.95 | LTA4H (0.35) | LTA4HFFAR1PPARDPPARAPDE10A | |
| SCHEMBL20100197 | 0.93 | S1PR1 (0.37) | LTA4HFFAR1PPARDPPARAPDE10A | |
| SCHEMBL20100201 | 0.93 | S1PR1 (0.37) | LTA4HFFAR1PPARDPPARAPDE10A | |
| SCHEMBL25457295 | 0.91 | LTA4H (0.36) | LTA4HFFAR1PPARDPDE10APDE3B | |
| SCHEMBL25457299 | 0.91 | LTA4H (0.36) | LTA4HFFAR1PPARDPPARAPDE10A | |
| SCHEMBL25781609 | 0.90 | LTA4H (0.38) | LTA4HPDE10APDE3BPDE3A | |
| SCHEMBL20225845 | 0.90 | LTA4H (0.35) | LTA4HFFAR1PPARDPPARAPDE10A | |
| SCHEMBL21326227 | 0.89 | LTA4H (0.35) | LTA4HFFAR1PPARDPPARAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548492-B1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORP (US) | 2023-07-05 | — | — | EP | claimed |
| US-11192894-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2021-12-07 | — | — | US | claimed |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2020-03-03 | — | — | US | claimed |
| EP-3548492-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2019-10-09 | — | — | EP | claimed |
| WO-2018102693-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2018-06-07 | — | — | WO | claimed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | claimed |
| EP-4279490-A2 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3548492-B1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORP (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3548492-B1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORP (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11192894-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192894-B2 | Cell impermeable coelenterazine analogues | PROMEGA CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-07-30 | — | — | US | disclosed |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-07-30 | — | — | US | disclosed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| WO-2018102693-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102693-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-06-07 | — | — | US | disclosed |
| US-20180119200-A1 | COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-05-03 | — | — | US | disclosed |
| US-20180119200-A1 | COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192894-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | LTA4H 1667/4885FFAR1 3646/4885PPARD 4392/4885 |
| US-10577370-B2 | Cell impermeable coelenterazine analogues | SI, GLB1, MRPL21 | LTA4H 1667/4885FFAR1 3646/4885PPARD 4392/4885 |
| US-20200239475-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | LTA4H 1667/4885FFAR1 3646/4885PPARD 4392/4885 |
| US-20180155350-A1 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | SI, GLB1, MRPL21 | LTA4H 1667/4885FFAR1 3646/4885PPARD 4392/4885 |
| US-20180119200-A1 | COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS | GLB1, SI, AADAC | LTA4H 2254/4885FFAR1 2584/4885PPARD 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.